Continuous Bioprocessing Market

Continuous Bioprocessing Market by Product (Chromatography, Filtration, Bioreactor, Media), Process (Upstream, Downstream), Scale of Operation (Commercial, Clinical), Application (mAbs, Vaccines, Cell & Gene Therapy), & End User - Global Forecast to 2028

Report Code: PH 8866 Nov, 2023, by marketsandmarkets.com

The global continuous bioprocessing market in terms of revenue was estimated to be worth $218 million in 2023 and is poised to reach $599 million by 2028, growing at a CAGR of 22.4% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the continuous bioprocessing market is largely driven by rising demand for biopharmaceuticals, advantages of continuous bioprocessing over batch/fed-batch mode, and emergence of integrated end-to-end continuous bioprocessing. On the other hand, high capital investment to limit entry for small players and stringent regulatory requirements are the major factors restraining the growth of this market.

Attractive Opportunities in the Continuous Bioprocessing Market

Continuous  Bioprocessing Market

To know about the assumptions considered for the study, Request for Free Sample Report

Continuous  Bioprocessing Market

Continuous Bioprocessing Market Dynamics

DRIVER: The emergence of integrated end-to-end continuous bioprocessing is projecting the market growth

End-to-end continuous bioprocessing is a process that integrates all of the steps involved in biopharmaceutical manufacturing into a single, continuous process. A growing number of companies are exploring continuous processing alongside intensification, which would lead to reduced production costs, real-time product releases, and predictive control. By chaining or combining serial steps in existing processes, continuous bioprocessing promises to transform biomanufacturing by reducing inter-campaign downtime, eliminating labor- and time-consuming steps, and reducing risk. Many companies are currently using continuous processes upstream, particularly in perfusion. Danaher Corporation (US), Sartorius AG (Germany), and Merck KGaA (Germany) are among the technology providers that have launched innovative automated perfusion systems and bioreactors.

RESTRAINT: High capital investment to limit entry for smaller players

Continuous bioprocessing often necessitates the use of sophisticated and specialized equipment, including bioreactors, chromatography systems, and automation technologies. Acquiring and maintaining these advanced systems requires a substantial initial capital outlay. End users must carefully evaluate their process and perform an economic analysis. In general, continuous manufacturing equipment has a higher capital investment because of the automation cost. The development and implementation of continuous biomanufacturing requires a substantial initial investment. Thus, the high capital investment needed for entry into the continuous bioprocessing market poses a significant challenge for smaller players.

OPPORTUNITY: PAT-enabled optimization of continuous bioprocesses

Process Analytical Technology (PAT) is a system of analytical tools that are used to monitor and control manufacturing processes. PAT can be used to optimize continuous bioprocessing by providing real-time data on the critical process parameters (CPPs) and critical quality attributes (CQAs) of the process. Process Analytical Technology (PAT) will play a key role in helping development scientists and manufacturing teams understand, control and optimize continuous bioprocesses. This real-time insight enables data-driven decision-making, allowing operators to make immediate adjustments when deviations or variations are detected.

CHALLENGE: Operational challenges

Process operational complexity in continuous bioprocessing presents multifaceted challenges that demand innovative solutions. Continuous manufacturing offers substantial benefits but also requires real-time monitoring and control of multiple critical parameters and quality attributes. Batch-fed processing has continued to increase in product titer as well as advances in a molecule's important quality properties as upstream and downstream continuous bioprocessing move towards greater scale and robustness. Batch techniques are still generally considered to be less complicated, less expensive, less risky, and less prone to failure than perfusion. With the advancement of relevant cell culture equipment, which now includes better pumps and controls, perfusion-purposed bioreactors, perfusion-tailored media, and general technological and operational advancements, alternating tangential flow (ATF) is starting to be produced relatively frequently.

Global Continuous Bioprocessing Ecosystem Analysis

The continuous bioprocessing market ecosystem comprises raw material suppliers, continuous bioprocessing product manufacturers, and end users such as pharmaceutical and biotechnology manufacturers, CROs, CDMOs, and academic & research institutes. Continuous bioprocessing products manufacturers provide chromatography systems and consumables, filtration systems and devices, bioreactors, cell culture media, cell lines, buffers and reagents, and other products.

Continuous  Bioprocessing Market Ecosystem

Pharmaceutical & biotechnology companies held a dominant share in end user segment in continuous bioprocessing industry.

Based on end user, the continuous bioprocessing market is segmented into pharmaceutical & biotechnology companies, contract research organizations and contract manufacturing organizations (CROs & CMOs), and academic & research institutes. In 2022, the pharmaceutical & biotechnology companies segment accounted for the largest share of the continuous bioprocessing market. The rising demand for biopharmaceuticals for the development of biosimilars in the treatment of chronic diseases is expected to be a key growth driver for this end-user segment. This has resulted in the growing focus of biopharmaceutical companies on the development of affordable biologics at lower costs. The adoption of continuous bioprocessing equipment is gradually increasing due to its wide applications in research & process development and the increasing manufacturing of biologics and biosimilars.

The filtration systems and devices segment of the continuous bioprocessing industry is expected to register fastest growth during the forecast period.

Based on product, the continuous bioprocessing market is segmented into chromatography systems & consumables; filtration systems & devices; bioreactors; cell culture media, cell lines, buffers, and reagents; and other products. The filtration systems & devices segment is estimated to grow at the highest CAGR during the forecast period. The high growth rate of this segment can be attributed to the increasing focus of mAbs in continuous bioprocessing, the growing clinical pipeline of mAbs awaiting regulatory approvals, and the advantages offered by monoclonal antibodies over other pharmaceutical drugs.

North America accounted for largest share in continuous bioprocessing industry in 2022.

Continuous  Bioprocessing Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Geographically, the continuous bioprocessing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest market for continuous bioprocessing. Many players operating in the continuous bioprocessing market, such as Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), and Repligen Corporation (US), have a strong presence in North America, with a wide customer base and established distribution channels. Similarly, an established biopharmaceutical industry in the region has also created a significant demand for continuous bioprocessing in this region. However, single use bioreactors associated issues such as leachables and extractables, and the presence of stringent regulations for disposable systems are expected to restrain the growth of the continuous bioprocessing market in North America.

Key players in the global continuous bioprocessing market include Danaher Corporation (US), Sartorius AG (Germany), Thermo Fisher Scientific Inc. (US), Repligen Corporation (US), Merck KGaA (Germany), 3M Company (US), Getinge AB (Sweden), Eppendorf SE (Germany), Corning Incorporated (US), Entegris (US), FUJIFILM Holdings Corporation (Japan), Meissner filtration products, Inc. (US), Kühner AG (Switzerland), Esco Lifesciences Group (Singapore), SATAKE MultiMix Corporation (Japan), Bionet (Spain), Stobbe Group (Switzerland), bbi-biotech GmbH (Germany), OmniBRx Biotechnologies (India),  Cell Culture Company, LLC (US), Pierre Guérin (France), Solida Biotech GmbH (Germany), Zellwerk GmbH (Germany), 3D Biotek, LLC (US), and FiberCell Systems Inc. (US).

Scope of the Continuous Bioprocessing Industry

Report Metric

Details

Market Revenue in 2023

$218 million

Projected Revenue by 2028

$599 million

Revenue Rate

Poised to Grow at a CAGR of 22.4%

Market Driver

The emergence of integrated end-to-end continuous bioprocessing is projecting the market growth

Market Opportunity

PAT-enabled optimization of continuous bioprocesses

This report categorizes the continuous bioprocessing market to forecast revenue and analyze trends in each of the following submarkets:

By Product

  • Chromatography Systems and Consumables
  • Filtration Systems and Devices
  • Bioreactors
  • Cell Culture Media, Cell Lines, Buffers and Reagents
  • Other Products

By Scale of Operation

  • Commercial Operations
  • Clinical Operations

By Process

  • Downstream Bioprocess
  • Upstream Bioprocess

By Application

  • Monoclonal Antibodies
  • Vaccines
  • Cell and Gene Therapy
  • Other Applications

By End User

  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organizations and Contract Manufacturing Organizations
  • Academic and Research Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • RoLATAM
  • Middle East & Africa
    • Middle East
    • Africa

Recent Developments of Continuous Bioprocessing Industry

  • In August 2023, Sartorius collaborated with Repligen Corporation and launched the Integrated bioreactor system. This system incorporates Repligen XCell ATF upstream intensification technology into Sartorius’ Biostat STR bioreactor to simplify intensified seed train and N perfusion implementation for biopharmaceutical manufacturers.
  • In July 2022, Cytiva expanded its operations with a new facility in Muskegon, Michigan. The new chromatography resins manufacturing site is part of Cytiva’s expansion investment.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 36)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SEGMENTATION 
          FIGURE 1 CONTINUOUS BIOPROCESSING MARKET SEGMENTATION
    1.4 YEARS CONSIDERED 
    1.5 CURRENCY CONSIDERED 
    1.6 LIMITATIONS 
    1.7 STAKEHOLDERS 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 41)
    2.1 RESEARCH DATA 
          FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 3 CONTINUOUS BIOPROCESSING MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS)
          FIGURE 6 ILLUSTRATIVE EXAMPLE OF SARTORIUS AG: REVENUE SHARE ANALYSIS (2022)
           2.2.1 INSIGHTS FROM PRIMARIES
                    FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
                    FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
    2.3 GROWTH FORECAST 
          FIGURE 9 CONTINUOUS BIOPROCESSING MARKET: CAGR PROJECTIONS (2023–2028)
          FIGURE 10 CONTINUOUS BIOPROCESSING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.4 DATA TRIANGULATION & MARKET BREAKDOWN 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 RECESSION IMPACT ANALYSIS 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 53)
    FIGURE 12 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2023 VS. 2028 (USD MILLION)
    FIGURE 15 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    FIGURE 16 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 17 GEOGRAPHICAL SNAPSHOT OF CONTINUOUS BIOPROCESSING MARKET
 
4 PREMIUM INSIGHTS (Page No. - 58)
    4.1 CONTINUOUS BIOPROCESSING MARKET OVERVIEW 
          FIGURE 18 RISING DEMAND FOR BIOPHARMACEUTICALS TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
    4.2 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT 
          FIGURE 19 CHROMATOGRAPHY SYSTEMS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022
    4.3 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION 
          FIGURE 20 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
    4.4 CONTINUOUS BIOPROCESSING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 21 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 61)
    5.1 INTRODUCTION 
          FIGURE 22 CONTINUOUS BIOPROCESSING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    5.2 MARKET DYNAMICS 
          TABLE 4 CONTINUOUS BIOPROCESSING MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Rising demand for biopharmaceuticals
                    5.2.1.2 Growing adoption among CDMOs and CMOs
                    5.2.1.3 Advantages of continuous bioprocessing over batch/fed-batch mode
                    5.2.1.4 Favorable regulatory & government support for innovative technologies
                    5.2.1.5 Emergence of integrated end-to-end continuous bioprocessing
           5.2.2 RESTRAINTS
                    5.2.2.1 High capital investments to limit entry for smaller players
                    5.2.2.2 Stringent regulatory requirements
           5.2.3 OPPORTUNITIES
                    5.2.3.1 High growth potential of emerging economies
                    5.2.3.2 PAT-enabled optimization of continuous bioprocessing
           5.2.4 CHALLENGES
                    5.2.4.1 Integration into existing manufacturing facilities
                    5.2.4.2 Operational challenges
    5.3 PRICING ANALYSIS 
          TABLE 5 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY KEY PLAYER (2022)
          TABLE 6 AVERAGE SELLING PRICE OF CONTINUOUS BIOPROCESSING PRODUCTS, BY REGION (2022)
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 23 REVENUE SHIFT AND NEW POCKETS FOR CONTINUOUS BIOPROCESSING PRODUCT PROVIDERS
    5.5 VALUE CHAIN ANALYSIS 
          FIGURE 24 CONTINUOUS BIOPROCESSING MARKET: VALUE CHAIN ANALYSIS
           5.5.1 RESEARCH & PRODUCT DEVELOPMENT
           5.5.2 RAW MATERIAL, MANUFACTURING, AND ASSEMBLY
           5.5.3 DISTRIBUTION AND AFTER-SALES SERVICES
    5.6 SUPPLY CHAIN ANALYSIS 
          FIGURE 25 CONTINUOUS BIOPROCESSING MARKET: SUPPLY CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 26 ECOSYSTEM MARKET MAP: CONTINUOUS BIOPROCESSING MARKET
          TABLE 7 CONTINUOUS BIOPROCESSING MARKET: ROLE IN ECOSYSTEM (SUPPLY/DEMAND SIDE)
    5.8 PATENT ANALYSIS 
          FIGURE 27 PATENT APPLICATIONS FOR CONTINUOUS BIOPROCESSING MARKET (JANUARY 2013–SEPTEMBER 2023)
    5.9 KEY CONFERENCES AND EVENTS 
          TABLE 8 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024)
    5.10 REGULATORY LANDSCAPE 
           5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                      TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                      TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                      TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                      TABLE 12 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.10.2 REGULATORY GUIDELINES
    5.11 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 13 CONTINUOUS BIOPROCESSING MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.11.1 THREAT OF NEW ENTRANTS
           5.11.2 THREAT OF SUBSTITUTES
           5.11.3 BARGAINING POWER OF SUPPLIERS
           5.11.4 BARGAINING POWER OF BUYERS
           5.11.5 INTENSITY OF COMPETITIVE RIVALRY
    5.12 TECHNOLOGY ANALYSIS 
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR CONTINUOUS BIOPROCESSING PRODUCTS
    5.14 KEY BUYING CRITERIA, BY END USER 
           FIGURE 29 KEY BUYING CRITERIA OF END USERS IN CONTINUOUS BIOPROCESSING MARKET
 
6 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT (Page No. - 86)
    6.1 INTRODUCTION 
           TABLE 14 CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
    6.2 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES 
           6.2.1 ADVANTAGES OF HIGH PRODUCTIVITY AND AFFORDABILITY TO DRIVE MARKET
                    TABLE 15 CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 16 NORTH AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 17 EUROPE: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 ASIA PACIFIC: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 LATIN AMERICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 MIDDLE EAST & AFRICA: CHROMATOGRAPHY SYSTEMS AND CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 FILTRATION SYSTEMS AND DEVICES 
           6.3.1 RISING TECHNOLOGICAL ADVANCEMENTS IN FILTRATION SYSTEMS TO DRIVE MARKET
                    TABLE 21 FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 22 NORTH AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 23 EUROPE: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 24 ASIA PACIFIC: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 25 LATIN AMERICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 26 MIDDLE EAST & AFRICA: FILTRATION SYSTEMS AND DEVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.4 BIOREACTORS 
           6.4.1 ABILITY TO ENABLE PROCESS INTENSIFICATION TO BOOST DEMAND
                    TABLE 27 BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 28 NORTH AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 29 EUROPE: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 30 ASIA PACIFIC: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 LATIN AMERICA: BIOREACTORS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 MIDDLE EAST & AFRICA: BIOREACTORS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.5 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS 
           6.5.1 INNOVATIONS IN CELL LINE DEVELOPMENT TO SUPPORT MARKET GROWTH
                    TABLE 33 CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 34 NORTH AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 35 EUROPE: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 36 ASIA PACIFIC: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 LATIN AMERICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 MIDDLE EAST & AFRICA: CELL CULTURE MEDIA, CELL LINES, BUFFERS, AND REAGENTS MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.6 OTHER PRODUCTS 
          TABLE 39 OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 40 NORTH AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 41 EUROPE: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 42 ASIA PACIFIC: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 43 LATIN AMERICA: OTHER PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 44 MIDDLE EAST & AFRICA: OTHER PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION)
 
7 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION (Page No. - 102)
    7.1 INTRODUCTION 
           TABLE 45 CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
    7.2 COMMERCIAL OPERATIONS 
           7.2.1 GROWING FOCUS ON COST-REDUCTION OF BIOSIMILARS TO PROPEL MARKET
                    TABLE 46 CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 47 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 48 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 49 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR COMMERCIAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
    7.3 CLINICAL OPERATIONS 
           7.3.1 INNOVATIONS IN R&D TESTING FOR THERAPEUTIC EFFICACY TO DRIVE MARKET
                    TABLE 52 CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 53 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 54 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 55 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CLINICAL OPERATIONS, BY REGION, 2021–2028 (USD MILLION)
 
8 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS (Page No. - 109)
    8.1 INTRODUCTION 
          TABLE 58 CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
    8.2 DOWNSTREAM BIOPROCESS 
           8.2.1 RISING TECHNOLOGICAL ADVANCEMENTS SUCH AS SPTFF AND MULTICOLUMN CHROMATOGRAPHY TO PROPEL MARKET
                    TABLE 59 CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 60 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 61 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR DOWNSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
    8.3 UPSTREAM BIOPROCESS 
           8.3.1 ADOPTION OF PERFUSION TECHNOLOGY TO SUPPORT MARKET GROWTH
                    TABLE 65 CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 66 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 67 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 68 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 70 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR UPSTREAM BIOPROCESS, BY REGION, 2021–2028 (USD MILLION)
 
9 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION (Page No. - 116)
    9.1 INTRODUCTION 
          TABLE 71 CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    9.2 MONOCLONAL ANTIBODIES 
           9.2.1 GROWING FOCUS ON THERAPEUTIC APPLICATIONS TO PROPEL MARKET
                    TABLE 72 CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 73 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 74 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021–2028 (USD MILLION)
    9.3 VACCINES 
           9.3.1 USE OF PERFUSION BIOREACTORS FOR VACCINE PRODUCTION TO DRIVE MARKET
                    TABLE 78 CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 79 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 80 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 83 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR VACCINES, BY REGION, 2021–2028 (USD MILLION)
    9.4 CELL & GENE THERAPY 
           9.4.1 INCREASING NUMBER OF CLINICAL TRIALS TO BOOST DEMAND
                    TABLE 84 CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 85 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 86 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 87 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 88 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 89 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION)
    9.5 OTHER APPLICATIONS 
          TABLE 90 CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
          TABLE 91 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 92 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 93 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 94 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 95 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)
 
10 CONTINUOUS BIOPROCESSING MARKET, BY END USER (Page No. - 128)
     10.1 INTRODUCTION 
             TABLE 96 CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
             10.2.1 RISING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET
                        TABLE 97 CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 98 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 99 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 100 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 101 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 102 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
     10.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) AND CONTRACT MANUFACTURING ORGANIZATIONS (CMOS) 
             10.3.1 RISING OUTSOURCING OF R&D SERVICES BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO PROPEL MARKET
                        TABLE 103 CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 104 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 105 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 106 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 107 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 108 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION)
     10.4 ACADEMIC & RESEARCH INSTITUTES 
             10.4.1 COLLABORATIONS BETWEEN PHARMACEUTICAL MANUFACTURERS AND RESEARCH INSTITUTES TO SUPPORT MARKET GROWTH
                        TABLE 109 CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 110 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 111 EUROPE: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 112 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 113 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 114 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
 
11 CONTINUOUS BIOPROCESSING MARKET, BY REGION (Page No. - 139)
     11.1 INTRODUCTION 
             TABLE 115 CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 30 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
             TABLE 116 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 117 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 118 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
             TABLE 119 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 120 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 121 NORTH AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 High biopharmaceutical R&D spending to drive market
                                      TABLE 122 US: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 123 US: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 124 US: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 125 US: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 126 US: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growing establishment of biopharmaceutical manufacturing facilities to propel market
                                      TABLE 127 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 128 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 129 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 130 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 131 CANADA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: RECESSION IMPACT
     11.3 EUROPE 
             TABLE 132 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 133 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 134 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
             TABLE 135 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 136 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 137 EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing initiatives for life sciences research to boost demand
                                      TABLE 138 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 139 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 140 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 141 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 142 GERMANY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 UK
                        11.3.2.1 Favorable government support for biotech clusters to propel market
                                      TABLE 143 UK: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 144 UK: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 145 UK: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 146 UK: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 147 UK: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Rising demand for mAbs and biologics to drive market
                                      TABLE 148 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 149 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 150 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 151 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 152 FRANCE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growth in pharma & biopharma industries to boost demand
                                      TABLE 153 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 154 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 155 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 156 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 157 ITALY: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing R&D funding by academic institutes to support market growth
                                      TABLE 158 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 159 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 160 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 161 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 162 SPAIN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 163 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 164 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                        TABLE 165 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 166 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 167 REST OF EUROPE: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 EUROPE: RECESSION IMPACT
     11.4 ASIA PACIFIC 
             FIGURE 31 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET SNAPSHOT
             TABLE 168 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 169 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 170 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
             TABLE 171 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 172 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 173 ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Government support and rising private investments to drive market growth
                                      TABLE 174 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 175 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 176 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 177 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 178 CHINA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Stringent regulatory guidelines for pharmaceutical drug safety to support market growth
                                      TABLE 179 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 180 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 181 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 182 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 183 JAPAN: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Growth in pharmaceutical industry to boost demand
                                      TABLE 184 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 185 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 186 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 187 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 188 INDIA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 SOUTH KOREA
                        11.4.4.1 Rising focus on quality manufacturing practices to drive market
                                      TABLE 189 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 190 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 191 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 192 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 193 SOUTH KOREA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 REST OF ASIA PACIFIC
                        TABLE 194 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 195 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                        TABLE 196 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 197 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 198 REST OF ASIA PACIFIC: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 ASIA PACIFIC: RECESSION IMPACT
     11.5 LATIN AMERICA 
             TABLE 199 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 200 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 201 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
             TABLE 202 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 203 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 204 LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Rising focus on cell & therapy manufacturing to support market
                                      TABLE 205 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 206 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 207 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 208 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 209 BRAZIL: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Increasing expansion of pharmaceutical companies to support market growth
                                      TABLE 210 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 211 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 212 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 213 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 214 MEXICO: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
                        TABLE 215 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                        TABLE 216 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                        TABLE 217 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                        TABLE 218 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 219 REST OF LATIN AMERICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.4 LATIN AMERICA: RECESSION IMPACT
     11.6 MIDDLE EAST & AFRICA 
             TABLE 220 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 221 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
             TABLE 222 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
             TABLE 223 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
             TABLE 224 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 225 MIDDLE EAST & AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.1 MIDDLE EAST
                        11.6.1.1 Increasing demand for biopharmaceutical drugs to drive market
                                      TABLE 226 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 227 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 228 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 229 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 230 MIDDLE EAST: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 AFRICA
                        11.6.2.1 Favorable initiatives for R&D investments to support market growth
                                      TABLE 231 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PRODUCT, 2021–2028 (USD MILLION)
                                      TABLE 232 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY SCALE OF OPERATION, 2021–2028 (USD MILLION)
                                      TABLE 233 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY PROCESS, 2021–2028 (USD MILLION)
                                      TABLE 234 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 235 AFRICA: CONTINUOUS BIOPROCESSING MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.3 MIDDLE EAST & AFRICA: RECESSION IMPACT
 
12 COMPETITIVE LANDSCAPE (Page No. - 199)
     12.1 OVERVIEW 
     12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
     12.3 REVENUE SHARE ANALYSIS 
             FIGURE 32 REVENUE SHARE ANALYSIS FOR KEY PLAYERS (2018−2022)
     12.4 MARKET SHARE ANALYSIS 
             FIGURE 33 CONTINUOUS BIOPROCESSING MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 236 CONTINUOUS BIOPROCESSING MARKET: INTENSITY OF COMPETITIVE RIVALRY
     12.5 COMPANY EVALUATION MATRIX 
             12.5.1 STARS
             12.5.2 PERVASIVE PLAYERS
             12.5.3 EMERGING LEADERS
             12.5.4 PARTICIPANTS
                        FIGURE 34 COMPANY EVALUATION MATRIX FOR KEY PLAYERS (2022)
             12.5.5 COMPANY FOOTPRINT ANALYSIS
                        TABLE 237 CONTINUOUS BIOPROCESSING MARKET: OVERALL COMPANY FOOTPRINT (2022)
             12.5.6 PRODUCT FOOTPRINT OF COMPANIES
                        TABLE 238 CONTINUOUS BIOPROCESSING MARKET: PRODUCT FOOTPRINT ANALYSIS
             12.5.7 REGIONAL FOOTPRINT OF COMPANIES
                        TABLE 239 CONTINUOUS BIOPROCESSING MARKET: REGIONAL FOOTPRINT ANALYSIS
     12.6 START-UP/SME EVALUATION MATRIX 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 RESPONSIVE COMPANIES
             12.6.3 DYNAMIC COMPANIES
             12.6.4 STARTING BLOCKS
                        FIGURE 35 COMPANY EVALUATION MATRIX FOR START-UP/SMES (2022)
             12.6.5 COMPETITIVE BENCHMARKING OF START-UP/SMES
                        TABLE 240 CONTINUOUS BIOPROCESSING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS
                        TABLE 241 CONTINUOUS BIOPROCESSING MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
     12.7 COMPETITIVE SCENARIOS AND TRENDS 
             12.7.1 PRODUCT LAUNCHES
                        TABLE 242 CONTINUOUS BIOPROCESSING MARKET: PRODUCT LAUNCHES & APPROVALS (JANUARY 2020−OCTOBER 2023)
             12.7.2 DEALS
                        TABLE 243 CONTINUOUS BIOPROCESSING MARKET: DEALS (JANUARY 2020−OCTOBER 2023)
             12.7.3 OTHER DEVELOPMENTS
                        TABLE 244 CONTINUOUS BIOPROCESSING MARKET: OTHER DEVELOPMENTS (JANUARY 2020−OCTOBER 2023)
 
13 COMPANY PROFILES (Page No. - 214)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     13.1 KEY PLAYERS 
             13.1.1 DANAHER CORPORATION
                        TABLE 245 DANAHER CORPORATION: BUSINESS OVERVIEW
                        FIGURE 36 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.2 SARTORIUS AG
                        TABLE 246 SARTORIUS AG: BUSINESS OVERVIEW
                        FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2022)
             13.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 247 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW
                        FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             13.1.4 REPLIGEN CORPORATION
                        TABLE 248 REPLIGEN CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 REPLIGEN CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.5 MERCK KGAA
                        TABLE 249 MERCK KGAA: BUSINESS OVERVIEW
                        FIGURE 40 MERCK KGAA: COMPANY SNAPSHOT (2022)
             13.1.6 3M COMPANY
                        TABLE 250 3M COMPANY: BUSINESS OVERVIEW
                        FIGURE 41 3M COMPANY: COMPANY SNAPSHOT (2022)
             13.1.7 GETINGE AB
                        TABLE 251 GETINGE AB: BUSINESS OVERVIEW
                        FIGURE 42 GETINGE AB: COMPANY SNAPSHOT (2022)
             13.1.8 EPPENDORF SE
                        TABLE 252 EPPENDORF SE: BUSINESS OVERVIEW
                        FIGURE 43 EPPENDORF SE: COMPANY SNAPSHOT (2022)
             13.1.9 CORNING INCORPORATED
                        TABLE 253 CORNING INCORPORATED: BUSINESS OVERVIEW
                        FIGURE 44 CORNING INCORPORATED: COMPANY SNAPSHOT (2022)
             13.1.10 ENTEGRIS
                        TABLE 254 ENTEGRIS: BUSINESS OVERVIEW
                        FIGURE 45 ENTEGRIS: COMPANY SNAPSHOT (2022)
             13.1.11 FUJIFILM HOLDINGS CORPORATION
                        TABLE 255 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2022)
             13.1.12 MEISSNER FILTRATION PRODUCTS, INC.
                        TABLE 256 MEISSNER FILTRATION PRODUCTS, INC.: BUSINESS OVERVIEW
             13.1.13 KÜHNER AG
                        TABLE 257 KÜHNER AG: BUSINESS OVERVIEW
             13.1.14 ESCO LIFESCIENCES GROUP
                        TABLE 258 ESCO LIFESCIENCES GROUP: BUSINESS OVERVIEW
             13.1.15 SATAKE MULTIMIX CORPORATION
                        TABLE 259 SATAKE MULTIMIX CORPORATION: BUSINESS OVERVIEW
     13.2 OTHER PLAYERS 
             13.2.1 BIONET
             13.2.2 STOBBE GROUP
             13.2.3 BBI-BIOTECH GMBH
             13.2.4 OMNIBRX BIOTECHNOLOGIES
             13.2.5 CELL CULTURE COMPANY, LLC
             13.2.6 PIERRE GUÉRIN
             13.2.7 SOLIDA BIOTECH GMBH
             13.2.8 ZELLWERK GMBH
             13.2.9 3D BIOTEK, LLC
             13.2.10 FIBERCELL SYSTEMS INC.
 
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
 
14 APPENDIX (Page No. - 264)
     14.1 DISCUSSION GUIDE 
     14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.3 CUSTOMIZATION OPTIONS 
     14.4 RELATED REPORTS 
     14.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global continuous bioprocessing market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the continuous bioprocessing market. The secondary sources used for this study include World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), National Institute for Bioprocessing Research and Training (NIBRT), Society for Biological Engineering (SBE), Bio-Process Systems Alliance (BPSA), European Patent Office (EPO), India Brand Equity Foundation (IBEF), Biotechnology Innovation Organization (BIO), National Center for Biotechnology Information (NCBI), BioPharm International, EvaluatePharma, ScienceDirect, Eurostat, research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global continuous bioprocessing market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across five major regions, including the Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

The following is a breakdown of the primary respondents:

Continuous  Bioprocessing Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the continuous bioprocessing market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Bottom-up Approach

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the single-use assemblies business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Continuous  Bioprocessing Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Top-down Approach

After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

Continuous  Bioprocessing Market Size, and Share

Data Triangulation

After arriving at the market size  from the market size estimation process explained above, the total market was divided into several segmentsand subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Continuous bioprocessing is a method used in the biopharmaceutical industry for the production of biologically derived products, such as biopharmaceuticals, vaccines, and other biologics, through continuous and uninterrupted operations. In the context of continuous bioprocessing, perfusion refers to a method of cell culture and bioproduction where a constant flow of fresh culture media is supplied to a bioreactor, and a corresponding volume of spent media, cells, or bioproducts is continuously removed. This is in contrast to traditional batch bioprocessing, where the culture is grown in a single vessel and harvested at the end of the production cycle.

Stakeholders

  • Continuous bioprocessing product manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and clinics)
  • R&D companies
  • Academic institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, and forecast the global continuous bioprocessing market based on the product, scale of operation, process, application, end user and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities and challenges)
  • To strategically analyze micro-markets with respect to individual growth trends, future prospects, and contributions to the overall continuous bioprocessing market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, and R&D activities in the continuous bioprocessing market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific continuous bioprocessing market into countries
  • A further breakdown of the Rest of European continuous bioprocessing market into countries
  • A further breakdown of the Rest of Latin American continuous bioprocessing market into countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization
Report Code
PH 8866
Published ON
Nov, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Continuous Bioprocessing Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback